- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 22.09. | Prenetics Global Ltd - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 21.09. | Prenetics Global Q2 2026 Earnings Call: Complete Transcript | 1 | Benzinga.com | ||
| 08.09. | StoneX reiterates Buy on Prenetics stock, keeps $40 target | 1 | Investing.com | ||
| 08.09. | Prenetics Global Ltd - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 27.08. | B.Riley initiates Prenetics stock coverage with buy rating on IM8 growth | 4 | Investing.com | ||
| 27.08. | B.Riley stuft Prenetics Aktie mit "Buy" ein - Wachstum durch IM8 im Fokus | 1 | Investing.com Deutsch | ||
| 26.08. | Prenetics Global CEO and CFO purchase $1M of shares in open market | 2 | Seeking Alpha | ||
| 26.08. | Prenetics Global Limited: Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results | 2 | GlobeNewswire (USA) | ||
| 26.08. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.08. | Prenetics Global Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 20.08. | Prenetics Global Limited: Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership | 1 | GlobeNewswire (USA) | ||
| 18.08. | Prenetics Q2 2026 slides: cash flow turns positive, $1B deal fuels growth | 10 | Investing.com | ||
| 18.08. | Prenetics Global GAAP EPS of -$0.53 beats by $0.01, revenue of $46.5M misses by $2.68M | 2 | Seeking Alpha | ||
| 18.08. | Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million | 747 | GlobeNewswire (Europe) | Total revenue of $46.5 million, up ~288% YoY (~3.9x); within the Company's guidance of $46-48 millionIM8 revenue of $45.0 million, up ~359% YoY (~4.6x); within the Company's guidance of $44-46 million... ► Artikel lesen | |
| 17.08. | Prenetics Global Q2 2026 Earnings Preview | 5 | Seeking Alpha | ||
| 17.08. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.08. | Prenetics Global Ltd - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 07.08. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.07. | Prenetics Raises $1 Billion For IM8 Via General Catalyst's Customer Value Fund | 3 | pulse2.com | ||
| 14.07. | Prenetics Global Limited: Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF) | 4 | GlobeNewswire (USA) |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 668,50 | +1,43 % | Kampf gegen Hautkrebs: Wie Vidac Pharma, Biofrontera und Regeneron an verschiedenen Stellen ansetzen | Auf der Jahrestagung der Europäischen Akademie für Dermatologie und Venerologie in Wien standen zuletzt neue Ansätze für die großflächige Behandlung von Hautschäden im Fokus. Der Kampf gegen Hautkrebs... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,400 | +2,63 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity | Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735
Monthly and Every-Other-Week Subcutaneous Regimens to also... ► Artikel lesen | |
| GUARDANT HEALTH | 147,82 | +0,14 % | Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy? | ||
| CANSINO BIOLOGICS | 4,160 | 0,00 % | CanSino Biologics Inc: Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New Opportunities | HONG KONG, Aug 27, 2026 - (ACN Newswire) - CanSino Biologics Inc. ('CanSinoBIO,' 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately... ► Artikel lesen | |
| SINO BIOPHARM | 0,616 | -1,93 % | SBP GROUP: TQC3721 Inhalation Suspension PDE3/4 Inhibitor Phase III Clinical Trial Completes Patient Enrollment | ||
| INNOVENT BIOLOGICS | 10,684 | +1,42 % | Innovent Biologics: Innovent Announces Phase 3 RESTORE-3 Study of SYCUME (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease | SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive... ► Artikel lesen | |
| BIO-TECHNE | 64,02 | -0,96 % | Bio-Techne opens GMP small molecule facility in Bristol, UK | ||
| GENSCRIPT BIOTECH | 4,740 | +1,28 % | HSI Opens Down 108 Pts; BABA-W Dips 1%; WUXI BIO Ebbs 3%+; GENSCRIPT BIO Slumps 10% | ||
| QUANTUM-SI | 1,520 | 0,00 % | H.C. Wainwright reiterates Quantum-Si stock rating on amino acid detection progress | ||
| SCILEX | 2,680 | +2,29 % | Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026 | PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and... ► Artikel lesen | |
| AKESO | 12,280 | +1,49 % | Akeso, Inc.: Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer | HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37... ► Artikel lesen | |
| ORIGIN AGRITECH | 0,595 | -9,85 % | Origin Agritech Ltd.: Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base | The sale brings approximately US$15.0 million to support working capital, R&D, new corn varieties, and market expansion, while the five-year lease-back maintains supply stability BEIJING, Oct. 01... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 40,310 | +1,72 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| NIKI BIOSOLUTIONS | 3,970 | 0,00 % | Niki BioSolutions, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript |
Das Unternehmen PRENETICS GLOBAL LIMITED kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 21,950 Euro und damit -0,23 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.